Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
La Oficina de Propiedad Intelectual de la Unión Europea cierra la solicitud de ayuda del Fondo para pymes (SME Fund) hasta la siguiente convocatoria en 2026.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
205
resultados
Última actualización
07/02/2026 [06:50:00]
Resumen de: WO2026030374A1
Provided herein is an ionizable lipid and a lipid nanoparticle composition including the ionizable lipid. The ionizable lipid and lipid nanoparticle composition are hypoxia responsive. Provided herein are also methods of delivering an agent to hypoxic tissue and treating disorders associated with hypoxia using the ionizable lipid and lipid nanoparticle composition. Such methods include treatment of placental related disorders.
Resumen de: WO2026028149A1
The present disclosure provides gRNAs for editing SERPINA1 and combinations of such gRNAs, nucleic acids encoding such gRNAs, vectors comprising such nucleic acids, RNPs comprising such gRNAs and endonucleases, pharmaceutical compositions comprising any of the foregoing, and kits comprising any of the foregoing. The present disclosure further provides methods related to such gRNAs, including methods of manufacturing, methods of effecting SERPINA1 gene editing, and methods of preventing, treating, or ameliorating a symptom of a target disease, disorder, or condition such as A1ATD.
Resumen de: WO2026029591A1
Provided is a transition metal dichalcogenide (TMD) composite, wherein the transition metal dichalcogenide (TMD) is in the form of a nanosheet, a fatty acid is bonded to the transition metal dichalcogenide (TMD) nanosheet, and the expression type of macrophages is determined according to a combination of the transition metal dichalcogenide and the fatty acid.
Resumen de: WO2026029593A1
Provided is a transition metal dichalcogenide (TMD) composite, wherein a TMD is in the form of a nanosheet, a fatty acid is conjugated to the TMD nanosheet, and the phenotype of macrophages is determined according to a combination of the TMD and the fatty acid.
Resumen de: WO2026029046A1
The present invention provides: a urea or carbamate lipid having a cyclic group in a side chain; lipid nanoparticles containing the lipid as a constituent component; and a pharmaceutical composition thereof. The present inventors have found a urea or carbamate lipid having a cyclic group in a side chain, and urea or carbamate lipid nanoparticles containing the lipid as a constituent component. It has been found that the lipid nanoparticles can express a protein in cells.
Resumen de: WO2026030568A1
Disclosed are branched poly(beta-amino ester) (PBAE) comprising a backbone having a ratio of diacrylate monomers and triacrylate monomers or diacrylate and tetraacrylate monomers, an amine sidechain, and an amine endgroup, and a nucleic acid, which are useful for the delivery of biomolecules, including the intracellular delivery of nucleic acids, which can be applied to almost any disease, ranging from cancer, to autoimmune diseases, to ocular diseases, to genetic disorders. These materials are particularly advantageous and enabled for delivery of mRNA and DNA to cells, including human cells. Compared to other PBAE nanoparticles, the disclosed NPs are smaller, more monodisperse, and more efficient at delivery and are useful and translatable as therapeutics.
Resumen de: WO2026026705A1
An atorvastatin calcium albumin nanoparticle, and a preparation method therefor and the use thereof. The atorvastatin calcium albumin nanoparticle consists of atorvastatin calcium and serum albumin in a mass ratio of 1:3-1:10. The preparation method comprises: adding absolute ethanol to atorvastatin calcium to obtain an organic phase, adding deionized water to serum albumin and adjusting the pH to obtain an aqueous phase, adding the organic phase in a dropwise manner to the aqueous phase, adding a glutaraldehyde solution for cross-linking, removing anhydrous ethanol, performing centrifugation, and collecting the lower precipitate layer to obtain the atorvastatin calcium albumin nanoparticle.
Resumen de: WO2026026697A1
A simvastatin albumin nanoparticle and preparation and use thereof. The simvastatin albumin nanoparticle is composed of simvastatin and serum albumin, wherein the mass ratio of simvastatin to serum albumin is 1:10-20. The simvastatin albumin nanoparticles are prepared by means of a nano-emulsification solvent volatilization method. The preparation method specifically comprises the preparation of an O/W emulsion and the preparation of albumin nanoparticles. The prepared nanoparticles have an average particle size of less than 500 nm, a polydispersity coefficient of less than 0.5, and an encapsulation efficiency of greater than 70%. The surface of the particles is negatively charged, and the zeta potential thereof is -31.25 mV. The nanoparticles can selectively target tumor cells, and exhibit different degrees of inhibitory effects on breast cancer, liver cancer, ovarian cancer, and colorectal cancer, with the strongest inhibitory effect observed on colorectal cancer.
Resumen de: WO2026025355A1
A taxane supramolecular nanocomposite. The supramolecular nanocomposite comprises a taxane active substance, including but not limited to paclitaxel, docetaxel, and cabazitaxel, as well as a self-assembling carrier, a high molecular polymer, and a dissolution promoter. The dissolution promoter may comprise one or more of alcohols, polybasic organic acids, and amino acids. Also disclosed are a preparation method and use of the supramolecular nanocomposite. The supramolecular nanocomposite is suitable for oral administration and topical application, providing effects such as increased local drug exposure concentration and efficacy, reduced systemic side effects, etc.
Resumen de: WO2026026869A1
The present invention designs and synthesizes a class of ionizable lipids. A lipid nanoparticle delivery system composed thereof can be used to efficiently and safely deliver nucleic acid drugs such as DNA and RNA, or small-molecule drugs, and not only has good encapsulation efficiency and stability, but also exhibits good safety and clearance rate in animals. They provide good delivery performance for nucleic-acid therapeutics or prophylactics, and have broad application prospects in fields related to drug delivery.
Resumen de: WO2026025348A1
An ultra-stable nanocomposite, comprising a core component, an auxiliary unit, a self-assembling carrier, and a high polymer. Also disclosed are a preparation method for the nanocomposite and use of the nanocomposite. The ratio of the core component to the auxiliary unit in the ultra-stable nanocomposite can be adjusted to prepare nanocomposites with varying proportions of the core component and the auxiliary unit. In one aspect, the performance attributes of the core component and the auxiliary unit are improved. Moreover, the stability of the assembled nanocomposite is also significantly improved, the particle size distribution of the nanocomposite is regulated, and the preparation process for the nanocomposite is simplified. The ability of the nanocomposite to resist interference from external substances is improved, and the structural integrity of the nanocomposite during gastrointestinal transport is maintained, thereby improving the delivery efficiency of functional ingredients.
Resumen de: WO2026025194A1
Provided here are compositions for delivery of leptin to a cell. The compositions can comprise a proteo-lipid vehicle comprising a recombinant fusion-associated small transmembrane (FAST) polypeptide and a nucleic acid encoding leptin or a functional fragment thereof. Also provided are methods for using the compositions.
Resumen de: WO2026029597A1
The present invention relates to a lipid nanoparticle composition containing a novel sterol lipid or a derivative thereof. The novel sterol lipid compound can replace part or all of the cholesterol, which is essential for the manufacture of lipid nanoparticles, so that the lipid nanoparticles are efficiently delivered to tissues other than the liver, thereby being able to be advantageously used in the development of gene therapeutic agents for various indications.
Resumen de: WO2026030286A1
Particles are provided that include a liposome having a negatively charged outer surface and a lipid-drug conjugate, a first layer of cationic polymer such as poly-L-arginine (PLR), that is non-covalently associated with the negatively charged outer surface of the liposome, and a second layer having a mixture of an anionic polymer and polyethylene glycol modified anionic polymer that is non-covalently associated with the first layer. The particles can be formulated as pharmaceutical compositions that are useful in methods that target neurological disorders such as brain tumors and other neurological diseases, and that can deliver and/or transport therapeutic drugs across the blood brain barrier.
Resumen de: WO2026030275A1
The present disclosure relates to RNA molecules encoding an EBV polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of infectious mononucleosis, and other diseases associated with EBV infection.
Resumen de: AU2023455215A1
Provided herein are novel constructs comprising gold nanoparticles bound to two types of cytokines, wherein the two types of cytokines comprise Tumor Necrosis Factor alpha (TNF ) and a cytokine selected from the group consisting of Interferon gamma (IFN ) and lnterleukin-12. Further provided is a method for treating cancer in a subject in need thereof.
Resumen de: AU2024315222A1
The present disclosure provides a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof, that is useful for forming particles (e.g., lipid nanoparticles) for delivery of nucleic acids. The present disclosure further provides particle compositions comprising the compound of formula I, as well as uses thereof.
Resumen de: AU2024314343A1
Disclosed are a method for preparing intracellular-derived nanovesicles and the use of the nanovesicles, in particular the use of the nanovesicles as a drug carrier and in the treatment of ophthalmic diseases. Intracellular-derived nanovesicles can be efficiently enriched using the method. The obtained intracellular nanovesicles, compared with small extracellular vesicles that are isolated from a cell supernatant and are mainly composed of exosomes, have different lipid, protein and nucleic acid components, have a higher yield, a smaller particle size, and a narrow particle size distribution range, and are more stable at different temperatures. The intracellular nanovesicles have a higher encapsulation efficiency and drug loading rate as a drug-loading carrier, and are more easily absorbed by tissue during in vivo administration, for example, the loaded drug administered in the form of an intravitreal injection can be absorbed by the retina more quickly. The intracellular nanovesicles can not only improve corneal injuries caused by wounds and alkali burns, but can also improve retinal damage and denaturation, and have very good application and research values in the pharmaceutical field.
Resumen de: AU2024329805A1
The disclosure provides for compositions that comprise nanocomplexes formed by complexing one or more therapeutic agents with nucleic acid fragments of varying lengths and sizes that are coated or complexed with protamine sulfate, and uses thereof, including for the treatment of cancer in a subject in need thereof.
Resumen de: AU2024327040A1
A method for preparing nucleic acid-containing lipid nanoparticles (NALNP) from a nucleic acid-containing neutral pH ionic salt solution and a lipid solution is provided. The method includes combining the nucleic acid-containing neutral pH ionic salt solution and the lipid solution and forming a combined mixture. The method further includes introducing an aqueous solution of lower ionic concentration than that of the neutral pH ionic salt solution into the combined mixture, thereby creating an ionic flux and forming the nucleic acid-containing lipid nanoparticles (NALNP).
Resumen de: EP4686417A1
The subject of the invention are nano/microcapsules with an average diameter of 0.1 µm to 5 µm having a coating with a thickness of 5 nm to 100 nm encapsulating a core, characterised in that the coating (4) of the nano/microcapsules (1) contains pectin supplied for the preparation of the nano/microcapsules (1) in the fruit pulp, and the core (3) is a water-oil nanoemulsion containing bioactive components (6, 7). The subject of the application is also a health-promoting product containing these nano/microcapsules and the method of obtaining them.
Resumen de: AU2024307171A1
A pharmaceutical composition containing a cationic lipid and the use thereof. Specifically, provided are a pharmaceutical composition comprising a carrier, the carrier comprising a cationic lipid, and the molar percentage of the cationic lipid to the carrier being greater than or equal to 10% and less than 50%.
Resumen de: CN121449524A
本发明涉及一种可离子化脂质化合物及其制备方法和应用，本发明提供的可离子化脂质化合物由极性氨基头和疏水尾构成。本发明通过改变可离子化脂质化物文库中包含的多种极性氨基头和疏水尾部构建多样化的具有低免疫原性的可离子化脂质化合物的制备及应用。具有生物可降解性能的新型可离子化脂质化合物与mRNA结合能力更强，且不过度引发相关的免疫炎性反应，此外由其合成的脂质纳米颗粒具有优异的理化特征，高的细胞摄取效率，溶酶体逃逸率及细胞和体内的高转染效率。
Resumen de: CN121445708A
本发明涉及一种靶向递送丁酸的OSA淀粉‑多糖互穿网络微球的制备方法，包括：S1、将多孔淀粉与辛烯基琥珀酸酐进行酯化反应，得到OSA淀粉；S2、将丁酸钠与玉米醇溶蛋白溶于醇溶液中，搅拌进行包埋，得到玉米醇溶蛋白‑丁酸钠；S3、将OSA淀粉与玉米醇溶蛋白‑丁酸钠进行反应，得到复合物；S4、将复合物分散于海藻酸钠溶液中，再滴加到氯化钙溶液中进行交联，得到OSA淀粉‑多糖凝胶微球，然后将其浸泡于第一浓度的壳聚糖溶液中进行一次包覆，再浸泡于第二浓度的壳聚糖溶液中进行二次包覆；第一浓度低于第二浓度，第一浓度和第二浓度相差不低于1wt％。本发明通过构建内核‑载体‑互穿网络外壳的结构，解决丁酸递送中包封率低、靶向性差、稳定性弱的难题。
Nº publicación: CN121445905A 03/02/2026
Solicitante:
中国科学院赣江创新研究院
Resumen de: CN121445905A
本发明涉及一种肿瘤内质网靶向的稀土纳米诊疗一体化制剂及其制备方法和应用，所述稀土纳米诊疗一体化制剂包括稀土核壳纳米颗粒以及负载在稀土核壳纳米颗粒表面的肿瘤靶向肽和内质网信号肽；所述稀土核壳纳米颗粒包括稀土纳米颗粒NaYbF4:Er/Ce/Zn和覆盖于NaYbF4表面的CaF2。该稀土纳米诊疗一体化制剂能够依赖精准的内质网靶向Ca²⁺释放，诱导肿瘤细胞钙过载，从而触发免疫原性细胞死亡并激活抗肿瘤免疫反应；同时，借助稀土纳米颗粒稳定的NIR‑Ⅱ区荧光特性，实现对肿瘤病灶的高灵敏成像与实时监测，兼具精准诊断与高效治疗的一体化优势。
BOPI
Sede Electrónica
